Latent TB Infection Testing Market

The main ways to diagnose LTBI are by placing a tuberculin skin test (TST) on the forearm or by getting a TB blood test, in addition to obtaining a chest radiograph (x-ray) if either one of these tests is positive. One-third of the world's population has LTBI. The TB germs are dormant (asleep) in the body.

Latent TB Infection Testing Market contains market size and forecasts of Latent TB Infection Testing in Global, including the following market information:

Global Latent TB Infection Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Latent TB Infection Testing market was valued at 1436.4 million in 2021 and is projected to reach US$ 2029.6 million by 2028, at a CAGR of 5.1% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Mantoux Test / Tuberculin Skin Test (TST) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Latent TB Infection Testing include Endo International plc (Par Sterile Products, LLC/JHP Pharmaceuticals, LLC), Pharmstandard (Generium Pharmaceutical), Sanofi S.A./Sanofi Pasteur Ltd., Statens Serum Institut (SSI), Autoimmun Diagnostika (AID) GmbH, Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., Haikou VTI Biological Institute (Vaccine Technologies, Inc.), Immunoshop India Pvt. Ltd. and Qiagen N.V., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Latent TB Infection Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Latent TB Infection Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Latent TB Infection Testing Market Segment Percentages, by Type, 2021 (%)

Mantoux Test / Tuberculin Skin Test (TST)

Interferon-Gamma Release Assay (IGRA)

Global Latent TB Infection Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Latent TB Infection Testing Market Segment Percentages, by Application, 2021 (%)

Hospitals

Public and Student Health

Physician Offices and Clinics

Others (Military, Correctional Facilities, Chronic Care Homes, and Others)

Global Latent TB Infection Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Latent TB Infection Testing Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Latent TB Infection Testing revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Latent TB Infection Testing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Endo International plc (Par Sterile Products, LLC/JHP Pharmaceuticals, LLC)

Pharmstandard (Generium Pharmaceutical)

Sanofi S.A./Sanofi Pasteur Ltd.

Statens Serum Institut (SSI)

Autoimmun Diagnostika (AID) GmbH

Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.

Haikou VTI Biological Institute (Vaccine Technologies, Inc.)

Immunoshop India Pvt. Ltd.

Qiagen N.V.

Quest Diagnostics, Inc. (Oxford Immunotec Global plc)

SD Biosensor, Inc.